Author:
Gao Lizhen,Wang Junqing,Chen Junlin,Zhang Xuelin,Zhang Manman,Wang Suling,Zhao Chen
Reference42 articles.
1. Carboplatin plus etoposide versus topotecan as second-line treatment for patients with sensitive relapsed small-cell lung cancer: An open-label, multicentre, randomised, phase 3 trial;Baize;The Lancet Oncology,2020
2. Anlotinib vs placebo as third- or further-line treatment for patients with small cell lung cancer: A randomised, double-blind, placebo-controlled phase 2 study;Cheng;British Journal of Cancer,2021
3. Advances in treatment of recurrent small cell lung cancer (SCLC): Insights for optimizing patient outcomes from an expert roundtable discussion;Das;Advances in Therapy,2021
4. Anlotinib plus platinum-etoposide as a first-line treatment for extensive-stage small cell lung cancer: A single-arm trial;Deng,2022
5. New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1);Eisenhauer;European Journal of Cancer,2009